Reporting of adverse events ONLY

Patients should always seek the advice of a doctor or pharmacist in case of adverse events.

If you wish to report an adverse event to ELC Group s.r.o., please find the contact information below:

00420 224 910 672

(from 09.00-17.30 CET)

00420 723 694 460

(non-stop 24/7)

To contact us about any other issue please call:

+420 22 491 0000or our regional offices.

Hlášení nežádoucích príhod

Pacienti by meli vždy požádat o radu svého lékare nebo lékárníka v prípade výskytu nežádoucích príhod.

Pokud chcete nahlásit nežádoucí príhodu spolecnosti ELC Group s r.o., prosím využijte kontaktních údaju níže:

00420 224 910 672

(09.00-17.30 CET)

00420 723 694 460

(non-stop 24/7)

Pro záležitosti, které se netýkaji farmakovigilance, kontaktujte prosím recepci:

+420 22 491 0000 nebo naše další pobočky.

Global regulatory affairs specialist ELC Group appoints former MHRA Expert Medical Assessor

World-renowned clinical scientist John Warren joins ELC GROUP’s Advisory Board

Cambridge, UK, 17th September, 2013 – ELC GROUP, one of the fastest-growing providers of regulatory affairs consulting services, today announced that John Warren, a former Expert Medical Assessor for the UK Medicines Healthcare products Regulatory Agency (MHRA) has joined the ELC GROUP Advisory Board.

John Warren is a world renowned clinical scientist holding triple specialist accreditation in the UK in General Medicine, Clinical Pharmacology and Cardiology. He is the author of over 100 publications in international journals on the physiology and pharmacology of the autonomic system and a book on the Endothelium.

John was a member of the European Scientific Advice Working Party from 2003 to 2010 and the European Pharmacokinetic Subgroup of the Efficacy Working Party from 2007 to 2008. He contributed to the EU Notes for Guidance on Asthma, COPD, ARDS and Bioequivalence. Previously he was a Senior Lecturer and Honorary Consultant at the National Heart & Lung Institute, London. He was also a Member of the Editorial Board of Clinical Pharmacology & Therapeutics and Microvascular Research and is currently Executive Editor for the British Journal of Clinical Pharmacology and member of the Joint Speciality Committee for Clinical Pharmacology of the Royal College of Physicians of London.

Speaking about the appointment, ELC GROUP CEO Marco Rubinstein said:

“We are honoured to have an expert of John’s calibre join our advisory board and bring his exceptional knowledge and experience to ELC GROUP.”

ELC Group’s Business Development Manager Akhil Jain added:

“We are very pleased to welcome John to ELC GROUP’s already exceptional Advisory Board. His academic contributions and vast experience in Regulatory Affairs make him a valuable new addition to our team.”

Commenting on his appointment, John Warren said: “ELC GROUP is a rapidly growing leading industry expert in global regulatory affairs consulting. I look forward to contributing to the continued strategic success of the company and bringing my experience of Regulatory Affairs to the work of the Advisory Board.”